SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Pacira BioSciences, Inc. – ‘10-K’ for 12/31/17 – ‘EX-32.1’

On:  Wednesday, 2/28/18, at 3:05pm ET   ·   For:  12/31/17   ·   Accession #:  1396814-18-9   ·   File #:  1-35060

Previous ‘10-K’:  ‘10-K’ on 3/1/17 for 12/31/16   ·   Next:  ‘10-K’ on 2/28/19 for 12/31/18   ·   Latest:  ‘10-K’ on 2/29/24 for 12/31/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/28/18  Pacira BioSciences, Inc.          10-K       12/31/17   87:10M

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.15M 
 2: EX-10.14    Material Contract                                   HTML    122K 
 3: EX-21.1     Subsidiaries List                                   HTML     21K 
 4: EX-23.1     Consent of Experts or Counsel                       HTML     24K 
 5: EX-23.2     Consent of Experts or Counsel                       HTML     24K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     29K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     29K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     23K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     23K 
16: R1          Document and Entity Information                     HTML     50K 
17: R2          Consolidated Balance Sheets                         HTML    108K 
18: R3          Consolidated Balance Sheets (Parenthetical)         HTML     43K 
19: R4          Consolidated Statements of Operations               HTML     91K 
20: R5          Consolidated Statements of Comprehensive Income     HTML     36K 
                (Loss)                                                           
21: R6          Consolidated Statements of Stockholders' Equity     HTML     96K 
22: R7          Consolidated Statements of Cash Flows               HTML    119K 
23: R8          Description of Business                             HTML     28K 
24: R9          Summary of Significant Accounting Policies          HTML    120K 
25: R10         Recent Accounting Pronouncements                    HTML     43K 
26: R11         Inventories                                         HTML     33K 
27: R12         Fixed Assets                                        HTML     43K 
28: R13         Goodwill and Intangible Assets                      HTML     41K 
29: R14         Accrued Expenses                                    HTML     35K 
30: R15         Debt                                                HTML     89K 
31: R16         Financial Instruments                               HTML    102K 
32: R17         Stockholders' Equity                                HTML     34K 
33: R18         Stock Plans                                         HTML    177K 
34: R19         Net Income (Loss) Per Share                         HTML     70K 
35: R20         Income Taxes                                        HTML    111K 
36: R21         Other Employee Benefits                             HTML     27K 
37: R22         Commercial Partners and Other Agreements            HTML     66K 
38: R23         Related Party Transactions                          HTML     31K 
39: R24         Commitments and Contingencies                       HTML     43K 
40: R25         Selected Quarterly Financial Data (Unaudited)       HTML     63K 
41: R26         Summary of Significant Accounting Policies          HTML    200K 
                (Policies)                                                       
42: R27         Summary of Significant Accounting Policies          HTML     86K 
                (Tables)                                                         
43: R28         Inventories (Tables)                                HTML     33K 
44: R29         Fixed Assets (Tables)                               HTML     37K 
45: R30         Goodwill and Intangible Assets (Tables)             HTML     32K 
46: R31         Accrued Expenses (Tables)                           HTML     34K 
47: R32         Debt (Tables)                                       HTML     60K 
48: R33         Financial Instruments (Tables)                      HTML     93K 
49: R34         Stockholders' Equity (Tables)                       HTML     31K 
50: R35         Stock Plans (Tables)                                HTML    138K 
51: R36         Net Income (Loss) Per Share (Tables)                HTML     71K 
52: R37         Income Taxes (Tables)                               HTML     76K 
53: R38         Commercial Partners and Other Agreements            HTML     47K 
                Commerical Partners and Other Agreements (Tables)                
54: R39         Commitments and Contingencies (Tables)              HTML     33K 
55: R40         Selected Quarterly Financial Data (Unaudited)       HTML     63K 
                (Tables)                                                         
56: R41         Summary of Significant Accounting Policies          HTML     26K 
                (Details)                                                        
57: R42         Summary of Significant Accounting Policies Summary  HTML     44K 
                of Significant Accounting Policies (Details 2)                   
58: R43         Summary of Significant Accounting Policies          HTML     37K 
                (Details 3)                                                      
59: R44         Summary of Significant Accounting Policies          HTML     37K 
                (Details 4)                                                      
60: R45         RECENT ACCOUNTING PRONOUNCEMENTS Recent Accounting  HTML     26K 
                Pronouncements (Details)                                         
61: R46         Inventories (Details)                               HTML     36K 
62: R47         Fixed Assets (Details)                              HTML     59K 
63: R48         Goodwill and Intangible Assets (Details)            HTML     65K 
64: R49         Goodwill and Intangible Assets Schedule of          HTML     26K 
                Intangible Assets (Details)                                      
65: R50         Accrued Expenses (Details)                          HTML     35K 
66: R51         Debt (Details)                                      HTML    157K 
67: R52         Debt (Details 2)                                    HTML     40K 
68: R53         Financial Instruments (Details)                     HTML     75K 
69: R54         Financial Instruments (Details 2)                   HTML     60K 
70: R55         Financial Instruments (Details 3)                   HTML     36K 
71: R56         Stockholders' Equity (Details)                      HTML     29K 
72: R57         Stockholders' Equity (Details 2)                    HTML     35K 
73: R58         Stock Plans (Details)                               HTML     71K 
74: R59         Stock Plans (Details 2)                             HTML     43K 
75: R60         Stock Plans (Details 3)                             HTML    155K 
76: R61         Net Income (Loss) Per Share (Details)               HTML     58K 
77: R62         Net Income (Loss) Per Share (Details 2)             HTML     39K 
78: R63         Income Taxes (Details)                              HTML    151K 
79: R64         Other Employee Benefits (Details)                   HTML     25K 
80: R65         Commercial Partners and Other Agreements (Details)  HTML    120K 
81: R66         Related Party Transactions (Details)                HTML     43K 
82: R67         Commitments and Contingencies (Details)             HTML     52K 
83: R68         Commitments and Contingencies (Details 2)           HTML     34K 
84: R69         Selected Quarterly Financial Data (Unaudited)       HTML     39K 
                (Details)                                                        
86: XML         IDEA XML File -- Filing Summary                      XML    149K 
85: EXCEL       IDEA Workbook of Financial Reports                  XLSX    105K 
10: EX-101.INS  XBRL Instance -- pcrx-20171231                       XML   2.70M 
12: EX-101.CAL  XBRL Calculations -- pcrx-20171231_cal               XML    245K 
13: EX-101.DEF  XBRL Definitions -- pcrx-20171231_def                XML    713K 
14: EX-101.LAB  XBRL Labels -- pcrx-20171231_lab                     XML   2.02M 
15: EX-101.PRE  XBRL Presentations -- pcrx-20171231_pre              XML   1.07M 
11: EX-101.SCH  XBRL Schema -- pcrx-20171231                         XSD    203K 
87: ZIP         XBRL Zipped Folder -- 0001396814-18-000009-xbrl      Zip    286K 


‘EX-32.1’   —   Certification — §906 – SOA’02


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Exhibit  
Exhibit 32.1

STATEMENT PURSUANT TO 18 U.S.C. §1350

Pursuant to 18 U.S.C. §1350, the undersigned certifies that this Annual Report on Form 10-K of Pacira Pharmaceuticals, Inc. for the year ended December 31, 2017, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Pacira Pharmaceuticals, Inc.

Date:
 
 
Chief Executive Officer and Chairman
(Principal Executive Officer)




Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:2/28/188-K
For Period end:12/31/17
 List all Filings 
Top
Filing Submission 0001396814-18-000009   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., May 4, 10:14:08.1am ET